Open AccessFirst experience of allogeneic haematopoietic stem cell transplantation in patients with mantle cell lymphoma with a mutation in the <i>TP53</i> gene
Author(s) -
Daria Koroleva,
Nelly G. Gabeeva,
M Y Drokov,
В. А. Васильева,
Б В Бидерман,
Svetlana Tsygankova,
Е. С. Булыгина,
G. М. Galstyan,
Andrey Sudarikov,
Tatiana Obukhova,
Л А Кузьмина,
Е Е Звонков,
Е Н Паровичникова,
В. Г. Савченко
Publication year - 2020
Publication title -
gematologiâ i transfuziologiâ
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.126
H-Index - 5
eISSN - 2411-3042
pISSN - 0234-5730
DOI - 10.35754/0234-5730-2020-65-4-483-500
Subject(s) - medicine , mantle cell lymphoma , hematopoietic stem cell transplantation , treosulfan , busulfan , transplantation , stem cell , lymphoma , oncology , melphalan , haematopoiesis , gastroenterology , chemotherapy , immunology , biology , genetics
. Mutations in the TP53 gene in patients with mantle cell lymphoma (MCL TP53+) are associated with a low response to intensive chemotherapy (CT) and adverse outcomes. Allogeneic haematopoietic stem cells transplantation (allo-HSCT) is a curative approach in MCL-TP53+ patients. Aim . Efcacy and safety assessment of allo-HSCT in MCL-TP53+ patients. Main ndings . During 2016–2020, allo-HSCT in MCL TP53+ was performed in three patients. Two of them were grafted from HLA-identical unrelated donors, and one — from a haploidentical donor. Pre-transplant conditioning was “udarabine + treosulfan + melphalan” in one case, and “udarabine + busulfan” — in the other two. In three patients, leukocyte and platelet counts were recovered at days +18 and +20, +17 and +21, +19 and +16 after allo-HSCT, respectively. Acute graft-versushost disease (aGVHD) was observed in all patients (grade I — in 2 patients, grade IV — in 1 patient). One patient developed chronic GVHD (cGVHD) of moderate grade. All three patients exhibited complete remission and 100% donor chimerism in allo-HSCT follow-up of 6, 15 and 40 months, respectively.